No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Eko Appoints Bryan Humbarger to the Position of Senior Vice President, Commercial

Editor: What To Know

  • “Eko's next generation of cardiac and pulmonary solutions are already making a difference for providers and their patients, and I am thrilled to bring my experience in cardiology and digital health to further accelerate the adoption of Eko's technology,” said Mr.
  • “Being at the forefront of delivering what's next in cardiovascular care is my passion, and I am thrilled to continue this journey at Eko, a company making a difference in how cardiac and pulmonary care is delivered.
  • “Bryan's leadership skills, proven ability to drive growth and passion for improving cardiac health will be key assets as Eko continues to expand adoption of our AI and telemedicine solutions,” said Connor Landgraf, CEO and co-founder of Eko.

Bryan Humbarger has been appointed to the position of Senior Vice President, Eko Commercial. In this role, Mr. Humbarger will oversee sales and commercial operations for Eko’s AI and telemedicine software platforms for health systems, practices and providers worldwide.

Mr. Humbarger most recently served as Vice President of Sales at cardiac digital health companies AliveCor and Heartflow. Previously, he spent nearly two decades gaining sales experience at medical device and technology companies, including Medtronic and Bioquell.

“Bryan’s leadership skills, proven ability to drive growth and passion for improving cardiac health will be key assets as Eko continues to expand adoption of our AI and telemedicine solutions,” said Connor Landgraf, CEO and co-founder of Eko. “Now more than ever, telemedicine is playing a critical role in caring for patients and Bryan will play a pivotal part in scaling operations for the company’s next phase of growth and continued expansion.”

Mr. Humbarger joins Eko following the achievement of several key company milestones, including the clearance of its cardiac AI algorithms by the U.S. Food and Drug Administration and the launch of Eko’s AI-powered telehealth platform.

“Eko’s next generation of cardiac and pulmonary solutions are already making a difference for providers and their patients, and I am thrilled to bring my experience in cardiology and digital health to further accelerate the adoption of Eko’s technology,” said Mr. Humbarger. “Being at the forefront of delivering what’s next in cardiovascular care is my passion, and I am thrilled to continue this journey at Eko, a company making a difference in how cardiac and pulmonary care is delivered.”

Subscribe to Medical Device News Magazine

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy